ICON PLC

NASDAQ ICLR

Download Data

ICON PLC Price to Earnings Ratio (P/E) on June 03, 2024: 81.71

ICON PLC Price to Earnings Ratio (P/E) is 81.71 on June 03, 2024, a 132.68% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.
  • ICON PLC 52-week high Price to Earnings Ratio (P/E) is 100.36 on December 28, 2023, which is 22.82% above the current Price to Earnings Ratio (P/E).
  • ICON PLC 52-week low Price to Earnings Ratio (P/E) is 35.12 on June 05, 2023, which is -57.02% below the current Price to Earnings Ratio (P/E).
  • ICON PLC average Price to Earnings Ratio (P/E) for the last 52 weeks is 64.02.
NASDAQ: ICLR

ICON PLC

CEO Dr. Steven A. Cutler MBA, Ph.D.
IPO Date May 15, 1998
Location Ireland
Headquarters South County Business Park, Dublin, Ireland, 18
Employees 41,150
Sector Healthcare
Industry Diagnostics & research
Description

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Similar companies

CRL

Charles River Laboratories

USD 207.93

-0.24%

LH

Laboratory Corporation of America Holdings

USD 195.01

0.05%

NEOG

Neogen Corporation

USD 13.72

4.33%

QGEN

Qiagen NV

USD 44.00

1.71%

TWST

Twist Bioscience Corp

USD 44.01

5.04%

WAT

Waters Corporation

USD 309.90

0.32%

StockViz Staff

September 8, 2024

Any question? Send us an email